IGF-1 LR3 10mg — Vial Spec, Reconstitution Math & COA

Overview & Vial Format: What a 10mg IGF-1 LR3 Vial Provides

A 10mg vial of IGF-1 LR3 contains 10,000 micrograms of the synthetic 83-amino-acid recombinant analog. Recombinant Long Arg3 IGF-1 is synthesized with a substitution of Glutamic acid for Arginine at position 3, combined with a 13-amino-acid N-terminal extension peptide. This structural modification severely impairs binding to endogenous Insulin-like Growth Factor Binding Proteins (IGFBPs), thereby extending the compound's active half-life in cellular culture media and experimental animal models relative to native IGF-1.

High-mass 10mg packaging is primarily sourced by academic facilities, biotechnology firms, and institutional research teams conducting continuous cell culture bioassays, receptor binding studies, or multi-cohort animal experiments. Because 10,000 mcg is a substantial mass for a potent peptide analog, precise volumetric reconstitution and disciplined aliquot handling are mandatory to maintain bioactivity across multiple experimental runs without subjecting the peptide to destructive freeze-thaw cycles.

Reconstitution Mathematics for 10mg Lyophilized Mass

Reconstituting a 10mg solid lyophilized cake requires accurate volumetric calculations to achieve desired working concentrations for micro-pipetting. Depending on the assay requirements, researchers select diluent volumes between 1.0 mL and 5.0 mL. Diluents typically consist of 0.1 M acetic acid or sterile 0.6% acetic acid solution (pH ~2.5 to 3.0) for initial solubilization, followed by downstream dilution into phosphate-buffered saline (PBS) containing 0.1% Bovine Serum Albumin (BSA) as a carrier protein to prevent surface adsorption.

When 1.0 mL of reconstituting diluent is added to 10mg of peptide, the resulting stock concentration is exactly 10.0 mg/mL (10,000 mcg/mL or 10 mcg/µL). When 2.0 mL of diluent is introduced, the stock concentration becomes 5.0 mg/mL (5,000 mcg/mL or 5.0 mcg/µL). Adding 3.0 mL yields a stock concentration of approximately 3.33 mg/mL (3,333 mcg/mL or 3.33 mcg/µL). Finally, diluting into 5.0 mL produces a 2.0 mg/mL stock (2,000 mcg/mL or 2.0 mcg/µL).

Researchers calculating specific working dilutions for cell culture assays or micro-injection plates can utilize the PX1 reconstitution calculator to quickly verify target concentration math and avoid pipetting errors in the laboratory.

Aliquot Planning and Freeze-Thaw Degradation Prevention

Because reconstituted peptide solutions degrade under repeated temperature shifts, single-use or weekly-use aliquot protocols must be established immediately following initial dissolution. Exposing a solubilized 10mg stock to repeated freeze-thaw cycles results in peptide aggregation, tertiary structure denaturation, and irreversible loss of receptor binding affinity.

For a standard 10mg reconstitution in 2.0 mL diluent (5.0 mg/mL final stock), a recommended aliquot scheme involves subdividing the solution into twenty 100 µL polypropylene micro-centrifuge tubes. Each 100 µL aliquot contains 500 mcg of active IGF-1 LR3. Individual aliquots can then be snap-frozen in liquid nitrogen or an ethanol-dry ice bath and stored at -80°C until required for a specific assay run.

When preparing working solutions from aliquots, thawing should occur slowly on ice. Once thawed, working solutions stabilized with 0.1% BSA carrier protein should be maintained at 2°C to 8°C and utilized within 24 to 48 hours to ensure consistent experimental reproducibility across all study cohorts.

PX1 Product Catalog & Availability Notice

PX1 Research emphasizes precise mass accuracy and physical stability across all catalog items. Depending on current synthesis schedules and manufacturing runs, exact unit sizes in stock may vary. While 10mg bulk configurations are manufactured specifically for high-throughput laboratories and enterprise partners, our standard high-purity stock item is supplied as a 1mg unit.

If your experimental design requires smaller unit sizes to minimize long-term reconstituted storage risks, explore our standard IGF-1 LR3 1mg product page. For institutional laboratories requiring bulk procurement or custom vial configurations beyond standard catalog sizes, high-volume arrangements can be submitted through our wholesale lab account portal. To browse our complete range of specialized growth factor analogs and laboratory reagents, view all research peptides available from PX1.

Analytical Quality Control: Lot-Matched COA Verification

Every production lot of IGF-1 LR3 synthesized for PX1 Research undergoes strict analytical verification prior to packaging and release. Because IGF-1 LR3 is a high-potency recombinant protein, strict purity standards are required to ensure target engagement without interference from synthesis byproducts, truncated fragments, or bacterial endotoxins.

Quality control testing utilizes High-Performance Liquid Chromatography (HPLC) to confirm peptide purity exceeding 98.0%, combined with Mass Spectrometry (MS) to verify correct molecular weight (approx. 9,111 Da). Furthermore, every fill lot undergoes Chromogenic LAL testing to ensure bacterial endotoxin levels remain below 0.1 EU/mg, preventing cell culture toxicity or non-specific inflammatory responses in in vitro assays. Researchers can verify batch-specific analytical reports directly on our COA database.

Preclinical Receptor Affinity and Mechanism of Action

Preclinical studies indicate that IGF-1 LR3 binds to the type 1 Insulin-like Growth Factor receptor (IGF-1R) with an affinity comparable to endogenous IGF-1. However, native IGF-1 is rapidly sequestered in extracellular spaces and circulatory systems by circulating IGFBPs (specifically IGFBP-3 and IGFBP-5), limiting its active biological half-life to minutes.

In vitro data demonstrate that the Arg3 substitution and N-terminal peptide elongation reduce affinity for IGFBPs by over 1,000-fold. Consequently, reconstituted IGF-1 LR3 remains unbound in culture media, continuously stimulating the autophosphorylation of the IGF-1R tyrosine kinase domain. This receptor activation triggers intracellular signaling cascades, primarily the PI3K/Akt and MAPK/ERK pathways, which regulate cell proliferation, protein synthesis, and inhibition of apoptosis in skeletal muscle myoblast lines (e.g., C2C12 cells) and cardiac tissue cultures.

Comparative Analysis: IGF-1 LR3 vs. Native IGF-1, Des(1-3)IGF-1, and MGF

When designing preclinical research protocols involving cell proliferation or tissue regeneration pathways, investigators frequently evaluate multiple signaling molecules within the IGF axis. Understanding the structural differences among these analogs is critical for choosing the appropriate reagent for specific bioassays.

Native IGF-1 serves as the baseline control but exhibits rapid inactivation in the presence of binding proteins. In contrast, Des(1-3)IGF-1 lacks the first three N-terminal amino acids (Gly-Pro-Glu), making it roughly 10 times more potent than native IGF-1 in vitro due to complete lack of IGFBP affinity, though it possesses a shorter systemic half-life than IGF-1 LR3. Meanwhile, PEG-MGF (Pegylated Mechano-Growth Factor), a splice variant of IGF-1 with an attached polyethylene glycol moiety, acts primarily on local muscle stem cell (satellite cell) recruitment rather than systemic growth factor receptors. For additional detailed comparisons on cellular signaling compounds, researchers can consult the PX1 research library.

Storage, Stability, and Handling in Laboratory Settings

To maintain analytical consistency, un-reconstituted (lyophilized) 10mg IGF-1 LR3 vials must be stored in a freezer at -20°C to -80°C immediately upon arrival. Under proper desiccated, sub-zero conditions, the lyophilized solid remains stable for up to 24 months from the manufacturing date.

Upon reconstitution with acidic diluent (e.g., 0.1M acetic acid), primary stock solutions are stable at 2°C to 8°C for up to 3 weeks. However, for long-term storage exceeding one month, stock solutions must be diluted into buffer containing a carrier protein (such as 0.1% BSA), aliquoted into single-use cryogenic vials, and frozen at -80°C. Avoid repeated exposure to ambient light and thermal fluctuations.

Protocol Design: High-Throughput In Vitro Assays vs. Animal Models

The 10mg vial size is particularly advantageous for laboratory designs that demand consistent batching across large sample cohorts. In high-throughput cell culture screens measuring muscle cell hypertrophy or metabolic rate shifts, consistent peptide concentration across hundreds of micro-titer well plates reduces batch-to-batch variability.

In rodent model investigations evaluating tissue protein synthesis, the extended half-life of IGF-1 LR3 allows lower administration frequencies compared to native IGF-1. However, because 10mg represents a large quantity of active reagent, researchers must prepare precise dilutions in physiological saline immediately prior to handling to prevent localized pH alterations or carrier protein precipitation.

Regulatory Status and Laboratory Compliance

IGF-1 LR3 (Long Arg3 IGF-1) is strictly classified as a research chemical intended exclusively for in vitro laboratory research, analytical testing, and preclinical animal experiments. It is not approved by the FDA or any foreign regulatory authority for human consumption, clinical diagnosis, therapy, or veterinary administration.

All products distributed by PX1 Research are supplied strictly for qualified research laboratories, academic institutions, and industrial research facilities. Misuse, human administration, or improper handling of research peptides violates terms of sale and institutional safety protocols.